JP2016504343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504343A5 JP2016504343A5 JP2015550082A JP2015550082A JP2016504343A5 JP 2016504343 A5 JP2016504343 A5 JP 2016504343A5 JP 2015550082 A JP2015550082 A JP 2015550082A JP 2015550082 A JP2015550082 A JP 2015550082A JP 2016504343 A5 JP2016504343 A5 JP 2016504343A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- ester
- acceptable salt
- diseases
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002148 esters Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12199801 | 2012-12-31 | ||
| EP12199801.7 | 2012-12-31 | ||
| EP13158812.1 | 2013-03-12 | ||
| EP13158812 | 2013-03-12 | ||
| PCT/EP2013/078040 WO2014102315A1 (en) | 2012-12-31 | 2013-12-27 | Selected macrolides with pde4-inhibiting activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504343A JP2016504343A (ja) | 2016-02-12 |
| JP2016504343A5 true JP2016504343A5 (enExample) | 2017-01-26 |
| JP6154026B2 JP6154026B2 (ja) | 2017-06-28 |
Family
ID=49886948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550082A Expired - Fee Related JP6154026B2 (ja) | 2012-12-31 | 2013-12-27 | Ｐｄｅ４阻害活性を有する選ばれたマクロライド |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9738676B2 (enExample) |
| EP (1) | EP2938623B1 (enExample) |
| JP (1) | JP6154026B2 (enExample) |
| CN (1) | CN104837855B (enExample) |
| CA (1) | CA2889251A1 (enExample) |
| DK (1) | DK2938623T3 (enExample) |
| ES (1) | ES2607638T3 (enExample) |
| HU (1) | HUE030196T2 (enExample) |
| PL (1) | PL2938623T3 (enExample) |
| PT (1) | PT2938623T (enExample) |
| WO (1) | WO2014102315A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019141256A1 (zh) | 2018-01-19 | 2019-07-25 | 沈阳福洋医药科技有限公司 | 可利霉素或其活性成分的用途 |
| CN110051680B (zh) * | 2018-01-19 | 2022-02-18 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1313751B1 (en) * | 2000-08-22 | 2008-09-17 | Basilea Pharmaceutica AG | New macrolides with antibacterial activity |
| US6995143B2 (en) * | 2002-02-28 | 2006-02-07 | Basilea Pharmaceutica Ag | Macrolides with antibacterial activity |
| ES2322775T3 (es) * | 2005-02-09 | 2009-06-26 | Basilea Pharmaceutica Ag | Nuevos macrolidos. |
| KR101589960B1 (ko) * | 2008-02-08 | 2016-01-29 | 바실리어 파마슈티카 아게 | Ｐｄｅ 억제를 통해 중재되는 질환의 치료를 위한 마크로라이드 |
| KR101617897B1 (ko) * | 2008-02-08 | 2016-05-03 | 바실리어 파마슈티카 아게 | 신규 마크로라이드 및 그의 용도 |
| WO2011018510A1 (en) * | 2009-08-13 | 2011-02-17 | Basilea Pharmaceutica Ag | New macrolides and their use |
-
2013
- 2013-12-27 WO PCT/EP2013/078040 patent/WO2014102315A1/en not_active Ceased
- 2013-12-27 JP JP2015550082A patent/JP6154026B2/ja not_active Expired - Fee Related
- 2013-12-27 DK DK13814988.5T patent/DK2938623T3/en active
- 2013-12-27 HU HUE13814988A patent/HUE030196T2/en unknown
- 2013-12-27 US US14/653,928 patent/US9738676B2/en not_active Expired - Fee Related
- 2013-12-27 CN CN201380064602.7A patent/CN104837855B/zh active Active
- 2013-12-27 CA CA2889251A patent/CA2889251A1/en not_active Abandoned
- 2013-12-27 PT PT138149885T patent/PT2938623T/pt unknown
- 2013-12-27 ES ES13814988.5T patent/ES2607638T3/es active Active
- 2013-12-27 PL PL13814988T patent/PL2938623T3/pl unknown
- 2013-12-27 EP EP13814988.5A patent/EP2938623B1/en not_active Not-in-force
-
2017
- 2017-08-03 US US15/667,894 patent/US10221206B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524883A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| JP2011132222A5 (enExample) | ||
| JP2009510044A5 (enExample) | ||
| JP2016535031A5 (enExample) | ||
| IL292465B1 (en) | Neuroactive compounds and methods of using them | |
| JP2014097964A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2016509051A5 (enExample) | ||
| JP2015509075A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| JP2016529306A5 (enExample) | ||
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| JP2016537338A5 (enExample) |